Program
Anti-CD39 Monoclonal Antibody IPH5201
Also written as “IPH5201 + durvalumab + standard chemotherapy” and “IPH5201”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 10 open or running | phase 1since Jan 7, 2020 | Jan 7, 2020 | none ahead |
| Innate Pharma | 11 open or running | phase 2since Feb 15, 2023 | Feb 15, 2023 | Jun 2027phase 2 · NCT05742607 |
- Named in AstraZeneca’s own pipeline as
IPH5201
, phase 2, as of Oct 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 7, 2020First study: phase 1 study in Advanced Solid TumorsNew to AstraZenecaAstraZeneca · NCT04261075 · 57 enrolled · United States, France, Spain and more
- Feb 15, 2023Innate Pharma’s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Innate PharmaInnate Pharma · NCT05742607 · 70 planned · United States, France, Greece and more
Ahead
- Jun 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungInnate Pharma · NCT05742607
TargetBeta
“A monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD39 monoclonal antibody IPH5201 spec…”NCIt, read by Claude
Other programs on ENTPD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014rule | elpiscience-suzhou-biopharma-ltd | phase 2 | 3 |
| Anti-PD-1/Anti-CD39 Bispecific Antibody BNT317rule | BioNTech | phase 2 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05742607Carcinoma, Non-Small-Cell Lung · United States, France, Greece and more | 2 | Recruiting | Innate Pharma | Jun 2027 | 70 |
| NCT04261075Advanced Solid Tumors · United States, France, Spain and more | 1 | Completed | AstraZeneca | Jun 16, 2022 | 57 |
How it is read
Names in the registry
- “IPH5201 + durvalumab + standard chemotherapy”, 1 entry
- “IPH5201”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.